Severe hypercalcemia following denosumab treatment in a juvenile patient

Nokitaka Setsu, Eisuke Kobayashi, Naofumi Asano, Naoko Yasui, Hiroshi Kawamoto, Akira Kawai, Keisuke Horiuchi

Research output: Contribution to journalArticlepeer-review

57 Citations (Scopus)


A 10-year-old boy diagnosed with unresectable giant cell tumor of bone in the sacrum was treated with a bone modifying agent denosumab. Administration of denosumab showed excellent clinical response without any major complications, and the tumor was surgically removed afterwards. However, 4 months after discontinuing denosumab, the patient developed severe hypercalcemia (15.2 mg/dl). There was a sharp surge in the levels of bone resorption markers, indicating that disregulated overt bone resorption after the discontinuation of denosumab led to hypercalcemia. The patient was treated with bisphosphonate and barely recovered from the life-threatening conditions. This case shows that a robust rebound of bone resorption may occur following cessation of denosumab and suggests that hypercalcemia is an underappreciated side effect of denosumab therapy in children.

Original languageEnglish
Pages (from-to)118-122
Number of pages5
JournalJournal of Bone and Mineral Metabolism
Issue number1
Publication statusPublished - Jan 1 2016
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology


Dive into the research topics of 'Severe hypercalcemia following denosumab treatment in a juvenile patient'. Together they form a unique fingerprint.

Cite this